Observational study of upper gastrointestinal haemorrhage in elderly patients given selective cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs.

What do we know about communicating risk? A brief review and suggestion for contextualising serious, but rare, risk, and the example of cox-2 selective and non-selective NSAIDs

An economic model of long-term use of celecoxib in patients with osteoarthritis

Valdecoxib is as effective as diclofenac in the management of rheumatoid arthritis with a lower incidence of gastroduodenal ulcers: results of a 26-week trial.

Prevention of Trastuzumab and Anthracycline-induced Cardiotoxicity Using Angiotensin-converting Enzyme Inhibitors or β-blockers in Older Adults With Breast Cancer.

Anemia and iron deficiency in gastrointestinal and liver conditions

Nonaspirin Nonsteroidal Anti-Inflammatory Drugs and Risk of Hemorrhagic Stroke: A Systematic Review and Meta-Analysis of Observational Studies.

Distinction from NSAIDs becoming blurred

Is pathology necessary to predict mortality among men with prostate-cancer?

Burden of non-communicable diseases among geriatric Nigerians in a rural hospital in resource-constrained setting of Eastern Nigeria

Patient-level pooled analysis of adjudicated gastrointestinal outcomes in celecoxib clinical trials: meta-analysis of 51,000 patients enrolled in 52 randomized trials

Observational study of upper gastrointestinal haemorrhage in elderly patients given selective cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs.

What do we know about communicating risk? A brief review and suggestion for contextualising serious, but rare, risk, and the example of cox-2 selective and non-selective NSAIDs

An economic model of long-term use of celecoxib in patients with osteoarthritis

Valdecoxib is as effective as diclofenac in the management of rheumatoid arthritis with a lower incidence of gastroduodenal ulcers: results of a 26-week trial.

Prevention of Trastuzumab and Anthracycline-induced Cardiotoxicity Using Angiotensin-converting Enzyme Inhibitors or β-blockers in Older Adults With Breast Cancer.

Anemia and iron deficiency in gastrointestinal and liver conditions

Nonaspirin Nonsteroidal Anti-Inflammatory Drugs and Risk of Hemorrhagic Stroke: A Systematic Review and Meta-Analysis of Observational Studies.

Distinction from NSAIDs becoming blurred

Is pathology necessary to predict mortality among men with prostate-cancer?

Burden of non-communicable diseases among geriatric Nigerians in a rural hospital in resource-constrained setting of Eastern Nigeria

Patient-level pooled analysis of adjudicated gastrointestinal outcomes in celecoxib clinical trials: meta-analysis of 51,000 patients enrolled in 52 randomized trials

Are selective COX 2 inhibitors superior to traditional non steroidal anti-inflammatory drugs?

Celecoxib exhibits the greatest potency amongst cyclooxygenase (COX) inhibitors for growth inhibition of COX-2-negative hematopoietic and epithelial cell lines.

Incidence of serious upper gastrointestinal bleeding/perforation in the general population: review of epidemiologic studies.

Limitation of the in vitro whole blood assay for predicting the COX selectivity of NSAIDs in clinical use.

Epidemiology of NSAID-related gastroduodenal mucosal injury.

Performance of comorbidity scores to control for confounding in epidemiologic studies using claims data.

Statistical Reviewer Briefing Document for the Advisory Committee

The coxibs, selective inhibitors of cyclooxygenase-2.

Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group.

Gastrointestinal Toxicity With Celecoxib vs Nonsteroidal Anti-inflammatory Drugs for Osteoarthritis and Rheumatoid Arthritis The CLASS Study: A Randomized Controlled Trial

Observational study of upper gastrointestinal haemorrhage in elderly patients given selective cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs.

What do we know about communicating risk? A brief review and suggestion for contextualising serious, but rare, risk, and the example of cox-2 selective and non-selective NSAIDs

An economic model of long-term use of celecoxib in patients with osteoarthritis

Valdecoxib is as effective as diclofenac in the management of rheumatoid arthritis with a lower incidence of gastroduodenal ulcers: results of a 26-week trial.

Prevention of Trastuzumab and Anthracycline-induced Cardiotoxicity Using Angiotensin-converting Enzyme Inhibitors or β-blockers in Older Adults With Breast Cancer.

Anemia and iron deficiency in gastrointestinal and liver conditions

Nonaspirin Nonsteroidal Anti-Inflammatory Drugs and Risk of Hemorrhagic Stroke: A Systematic Review and Meta-Analysis of Observational Studies.

Distinction from NSAIDs becoming blurred

Is pathology necessary to predict mortality among men with prostate-cancer?

Burden of non-communicable diseases among geriatric Nigerians in a rural hospital in resource-constrained setting of Eastern Nigeria

Patient-level pooled analysis of adjudicated gastrointestinal outcomes in celecoxib clinical trials: meta-analysis of 51,000 patients enrolled in 52 randomized trials

Are selective COX 2 inhibitors superior to traditional non steroidal anti-inflammatory drugs?

Celecoxib exhibits the greatest potency amongst cyclooxygenase (COX) inhibitors for growth inhibition of COX-2-negative hematopoietic and epithelial cell lines.

Incidence of serious upper gastrointestinal bleeding/perforation in the general population: review of epidemiologic studies.

Limitation of the in vitro whole blood assay for predicting the COX selectivity of NSAIDs in clinical use.

Epidemiology of NSAID-related gastroduodenal mucosal injury.

Performance of comorbidity scores to control for confounding in epidemiologic studies using claims data.

Statistical Reviewer Briefing Document for the Advisory Committee

The coxibs, selective inhibitors of cyclooxygenase-2.

Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group.

Gastrointestinal Toxicity With Celecoxib vs Nonsteroidal Anti-inflammatory Drugs for Osteoarthritis and Rheumatoid Arthritis The CLASS Study: A Randomized Controlled Trial